RBC on Beam Therapeutics Inc (BEAM): 'we view the data as incrementally positive'
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated a Sector Perform rating and $26.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
